| scholarly article | Q13442814 |
| P2093 | author name string | Hua Zhang | |
| Yan Zhang | |||
| Douglas Yee | |||
| Annabell Oh | |||
| Xianke Zeng | |||
| P2860 | cites work | ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery | Q24649645 |
| Autophagy in the Pathogenesis of Disease | Q27860558 | ||
| How to interpret LC3 immunoblotting | Q29614175 | ||
| Insulin and insulin-like growth factor signalling in neoplasia | Q29619495 | ||
| The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. | Q33745823 | ||
| Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation | Q33818935 | ||
| Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy | Q33934670 | ||
| The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex | Q34103230 | ||
| Emerging targeted therapies for breast cancer | Q34119550 | ||
| Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes | Q34157626 | ||
| Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor | Q34172489 | ||
| Dasatinib induces autophagic cell death in human ovarian cancer | Q34286944 | ||
| The IGF system and breast cancer | Q34376362 | ||
| The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models | Q35058305 | ||
| Targeted therapy: wave of the future. | Q36065510 | ||
| MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. | Q36134468 | ||
| ARF, autophagy and tumor suppression. | Q37155201 | ||
| Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo | Q37287624 | ||
| IGF-1 receptor inhibitors in clinical trials--early lessons | Q37309022 | ||
| Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells | Q37327775 | ||
| Regulation of breast cancer metastasis by IGF signaling | Q37334032 | ||
| Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine | Q37370640 | ||
| Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro | Q37389178 | ||
| Autophagy in cellular growth control | Q37680207 | ||
| Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved | Q37688986 | ||
| Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer | Q39647932 | ||
| Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. | Q39698158 | ||
| MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? | Q39834203 | ||
| Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. | Q39877535 | ||
| A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo | Q40099249 | ||
| MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research | Q40227151 | ||
| A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. | Q40616617 | ||
| Mechanism of action of topoisomerase II-targeted antineoplastic drugs | Q41315190 | ||
| Structure and function of the insulin-like growth factor I receptor | Q41727239 | ||
| Insulin-like growth factor receptor expression and function in human breast cancer | Q41753631 | ||
| Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting | Q42139574 | ||
| Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer | Q45151891 | ||
| Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. | Q45950196 | ||
| Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors | Q46972238 | ||
| Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1 | Q81165876 | ||
| Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells | Q81380006 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| cytotoxicity | Q246181 | ||
| PQIP | Q27162600 | ||
| P304 | page(s) | 117-126 | |
| P577 | publication date | 2011-08-18 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor | |
| P478 | volume | 133 |
| Q38772200 | A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques |
| Q37029389 | A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal |
| Q35837734 | A tale of two receptors: insulin and insulin-like growth factor signaling in cancer |
| Q34336988 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? |
| Q36545498 | IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide |
| Q34391968 | Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. |
| Q36790586 | Insulin-like growth factor receptor inhibitors: baby or the bathwater? |
| Q35136532 | Lipid Signaling in Tumorigenesis |
| Q36615766 | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors |
| Q44636888 | Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. |
| Q26826380 | Targeting insulin and insulin-like growth factor signaling in breast cancer |
| Q36708178 | Targeting the insulin-like growth factor-1 receptor in human cancer |
| Q35609517 | The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link |
| Q26852910 | The links between insulin resistance, diabetes, and cancer |
Search more.